French pharmaceutical giant Sanofi is currently the leader in the long-acting insulin space. Its product Lantus is used by diabetes patients around the world, and it's currently the company's best selling drug. However, what are the challenges up ahead for Sanofi? Will Lantus' multibillion-dollar sales continue in perpetuity? What about Sanofi's other insulin drug Apidra -- is this product a weakness in the company's diabetes franchise?
In the following video, health care analyst Max Macaluso discusses these topics and probes Sanofi's strengths and weaknesses.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article The Weaknesses in Sanofi's Diabetes Franchise originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.